Literature DB >> 20113458

Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation.

S-H Kim1, S-O Lee, I-A Park, S J Park, S-H Choi, Y S Kim, J H Woo, S-K Park, J S Park, S C Kim, D J Han.   

Abstract

BACKGROUND: The presence of latent tuberculosis (TB) infection (LTBI) should be evaluated before kidney transplantation. Although a new T cell-based assay for diagnosing LTBI gave promising results, this assay has not yet been compared with the tuberculin skin test (TST) for diagnosing LTBI in renal transplant candidates before transplantation. PATIENTS AND METHODS: All adult patients admitted to a single institute for renal transplantation over a 1-year period were prospectively enrolled. A clinically predictive risk of LTBI was defined as: (i) recent close contact with a person with pulmonary TB; (ii) abnormal chest radiography; (iii) a history of untreated or inadequately treated TB; or (iv) a new infection (i.e., a recent conversion of TST).
RESULTS: Of 209 renal recipients, 47 (22%) had a positive TST> or =5 mm, 21 (10%) had a positive TST> or =10 mm, 65 (30%) had a positive T-SPOT.TB test, and 25 (12%) had an indeterminate T-SPOT.TB test. The induration size of TST was significantly associated with a high positivity rate on T-SPOT.TB (P<0.001). Agreement between T-SPOT.TB test and TST> or =10 mm was fair (k=0.24, 95% confidence interval 0.11-0.36). However, neither univariate nor multivariate analysis showed any association between the clinical risk for LTBI and positivity on T-SPOT.TB or TST.
CONCLUSION: T-SPOT.TB test was more frequently positive than TST in renal transplant candidates. However, further longitudinal studies are awaited to determine whether the ability of T-SPOT.TB assay to detect LTBI in renal transplant recipients can better predict the development of TB than can TST after transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113458     DOI: 10.1111/j.1399-3062.2010.00495.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  7 in total

1.  Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: A study and review of the literature.

Authors:  J Grant; J Jastrzebski; J Johnston; A Stefanovic; J Jastrabesky; K Elwood; D Roscoe; R Balshaw; E Bryce
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  Comparison of the tuberculin skin test and interferon-γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation.

Authors:  S Y Kim; G S Jung; S K Kim; J Chang; M S Kim; Y S Kim; Y A Kang; D J Joo
Journal:  Infection       Date:  2012-07-17       Impact factor: 3.553

Review 3.  Update of the mechanism and characteristics of tuberculosis in chronic kidney disease : Review article.

Authors:  Xuehan Zhang; Pingshan Chen; Gaosi Xu
Journal:  Wien Klin Wochenschr       Date:  2022-03-07       Impact factor: 2.275

4.  Concordance of the tuberculin skin test and T-SPOT(®).TB test results in kidney transplant candidates.

Authors:  Roya Sherkat; Majid Yaran; Parisa Shoaie; Mojgan Mortazavi; Shahrzad Shahidi; Hossein Hamidi; Shiva Seirafian; Shahram Taheri; Ziba Farajzadegan; Soodabeh Rostami
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

5.  Comparison of interferon gamma release assay & tuberculin skin tests for diagnosis of latent tuberculosis in patients on maintenance haemodialysis.

Authors:  Sanjay K Agarwal; Urvashi B Singh; Sabahat H Zaidi; Sanjay Gupta; Ravinder M Pandey
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

Review 6.  Diagnosis and treatment of latent tuberculosis infection.

Authors:  Seung Heon Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-04-02

Review 7.  Mycobacterial infections in solid organ transplant recipients.

Authors:  Harun Ur Rashid; Nura Afza Salma Begum; Tasnuva Sarah Kashem
Journal:  Korean J Transplant       Date:  2021-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.